Laboratorio Elea Phoenix S.A.
17 clinical trials · Sponsor
◉ Watch Laboratorio Elea Phoenix S.A.
| Record | Firm | Date |
|---|---|---|
| Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms (NCT06629389) | Laboratorio Elea Phoenix S.A. | 2024-11-28 |
| Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC (NCT05668650) | Laboratorio Elea Phoenix S.A. | 2023-08-15 |
| Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease (NCT04897516) | Laboratorio Elea Phoenix S.A. | 2021-07-28 |
| Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) (NCT04560881) | Laboratorio Elea Phoenix S.A. | 2020-09-16 |
| Telmisartan for Treatment of COVID-19 Patients (NCT04355936) | Laboratorio Elea Phoenix S.A. | 2020-05-19 |
| Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19 (NCT04381884) | Laboratorio Elea Phoenix S.A. | 2020-05-18 |
Track Laboratorio Elea Phoenix S.A. automatically
Every clearance here is in the API, with alerts when new ones post.